Ellence, Epirubicin Newswire

Ellence, Epirubicin Newswire

Comprehensive Real-Time News Feed for Ellence, Epirubicin (generic).

Results 1 - 20 of 23 in Ellence, Epirubicin (generic)

  1. Circadian rhythms of factors involved in luteal regression are...Read the original story

    Friday Jun 15 | CSIRO Publishing

    Magali del C. de la Vega A , Maria B. Delsouc A , Ivana Ponce B , Vicente Ragusa A B , Sandra Vallcaneras A , Ana C. Anzulovich B C and Marilina Casais A C A Laboratorio de Biologia de la Reproduccion, Facultad de Quimica, Bioquimica y Farmacia, Instituto Multidisciplinario de Investigaciones Biologicas, San Luis, Universidad Nacional de San Luis, Ejercito de los Andes 950, CP D5700HHW, San Luis, Argentina. B Laboratorio de Cronobiologia, Facultad de Quimica, Bioquimica y Farmacia, Instituto Multidisciplinario de Investigaciones Biologicas, San Luis, Universidad Nacional de San Luis, Ejercito de los Andes 950, CP D5700HHW, San Luis, Argentina.

    Comment?

  2. Synovial Sarcoma Treatment Market, by Treatment Type ChemotherapyRead the original story

    May 19, 2018 | Digital Pro Sound

    Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults.

    Comment?

  3. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell...Read the original story w/Photo

    May 9, 2018 | Oncogene

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  4. Radiogenic angiosarcoma of the breast: case report and systematic review of the literatureRead the original story w/Photo

    Apr 23, 2018 | BioMed Central

    Radiogenic angiosarcoma of the breast is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized therapy for this type of malignancy.

    Comment?

  5. Venous invasion as a risk factor for recurrence after gastrectomy...Read the original story w/Photo

    Jan 29, 2018 | BioMed Central

    Although adjuvant chemotherapy with S-1 after curative gastrectomy has been performed as a standard treatment for Stage II and III gastric cancer in Japan, patients with Stage III GC still have a high incidence of recurrence and a poor prognostic outcome. The aim of this study was to investigate risk factors for recurrence in patients with Stage III GC despite of curative gastrectomy followed by adjuvant chemotherapy, suggesting an indicator for more intensive management.

    Comment?

  6. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteinsRead the original story w/Photo

    Jan 5, 2018 | BioMed Central

    Cancer cell resistance to therapeutics can result from acquired or de novo-mediated factors. Here, we have utilised advanced breast cancer cell culture models to elucidate de novo doxorubicin resistance mechanisms.

    Comment?

  7. Anti Tumor Drugs Market: Future Market Projections for Forthcoming YearsRead the original story w/Photo

    Dec 27, 2017 | SBWire

    Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations.

    Comment?

  8. Experimental drug trial seeks to improve treatment for head and neck cancerRead the original story w/Photo

    Nov 24, 2017 | PhysOrg Weblog

    A trial to test an experimental drug in patients with head and neck cancer launches in the UK today , through the Combinations Alliance - a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres Network. Researchers want to find out whether using Astra Zeneca's AZD1775 experimental compound, in combination with chemotherapy before surgery or with chemotherapy and radiotherapy after surgery, is more effective and reduces the risk of the cancer returning.

    Comment?

  9. A novel chemotherapeutic sensitivity-testing system based on collagen ...Read the original story w/Photo

    Nov 7, 2017 | BioMed Central

    Patients suffering from advanced stage hepatocellular carcinoma often exhibit a poor prognosis or dismal clinical outcomes due to ineffective chemotherapy or a multi-drug resistance process. Thus, it is urgent to develop a new chemotherapeutic sensitivity testing system for HCC treatment.

    Comment?

  10. Transcatheter arterial chemoembolization plus sorafenib versus...Read the original story w/Photo

    Nov 5, 2017 | BioMed Central

    Many studies have combined sorafenib with transcatheter arterial chemoembolization to treat patients with advanced hepatocellular carcinoma , but the results are disputable. Thus, we conducted this meta-analysis to assess the efficacy and safety of the combination treatment in patients with advanced HCC.

    Comment?

  11. Determining patient radiosensitivity from blood samplesRead the original story w/Photo

    Oct 10, 2017 | PhysOrg Weblog

    How much radiation or chemotherapy can a certain person handle? With help from blood or tissue testing, it may be possible to answer this question in advance, which in turn could improve treatment, as research at Sahlgrenska Academy shows. "Although our research is at an early stage and we need to do more studies, the idea is that it will be possible to test sensitivity and prevent extremely sensitive patients from having serious side effects," says Sherin Mathew, a doctoral graduate at the Institute of Biomedicine.

    Comment?

  12. Japanese researchers find new way for increasing effectiveness of drug delivery to brain tumorsRead the original story w/Photo

    Sep 13, 2017 | Medical News

    For a cancer drug to be successful, it needs to reach the malignant tumor site. Researchers in Japan have now found a way for increasing the effectiveness of drug delivery to certain types of brain tumors, by packing epirubicin, a known antitumor agent, in specially designed polymeric micelles.

    Comment?

  13. New Way to Deliver Chemo Agent Helps Reach Brain TumorsRead the original story w/Photo

    Sep 12, 2017 | Medgadget

    While there are fairly effective medications that can kill brain tumors, getting them to their targets is so challenging that they're often next to useless for cancers of the brain. Japanese scientists from Kawasaki Institute of Industrial Promotion, The University of Tokyo, and Tokyo Institute of Technology have developed a shell for epirubicin, a common chemotherapy agent, that helps it to cross the blood-brain barrier and reach a tumor significantly more effectively than before.

    Comment?

  14. Surface modification of nanomedicines enhances their therapeutic effect on brain tumorsRead the original story w/Photo

    Sep 11, 2017 | PRWeb

    Researchers affiliated with the Kawasaki INnovation Gateway at SKYFRONT, have found a way for increasing the effectiveness of drug delivery to certain types of brain tumors, by packing epirubicin, a known antitumor agent, in specially designed polymeric micellessuccess. These results are reported in the Journal of Controlled Release and are important for developing cancer treatments.

    Comment?

  15. Patients feel psycho-social impact of chemo more acutely than physical side effectsRead the original story w/Photo

    Sep 9, 2017 | PhysOrg Weblog

    The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid show that socio-psychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in similar studies carried out previously. The side effects of chemotherapy seriously impact cancer patients' daily lives, and managing them is a longtime concern for doctors.

    Comment?

  16. New trial confirms superiority of triplet regimen over standard care...Read the original story w/Photo

    Sep 8, 2017 | Medical News

    The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid. Survival in resectable esophago-gastric cancer is poor.

    Comment?

  17. New data confirms superiority of docetaxel based triplet therapy in gastric cancerRead the original story w/Photo

    Sep 8, 2017 | PhysOrg Weblog

    The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid. Survival in resectable oesophago-gastric cancer is poor.

    Comment?

  18. Medical Prognosis Institute Publishes Half-Year Report For The First Half Of 2017Read the original story

    Aug 30, 2017 | BioSpace

    Hoersholm, Denmark, August 31, 2017 - Medical Prognosis Institute A/S announces the company's Half-year report for the period January-June 2017. The report is available as an attached document to this press release and on the company's website .

    Comment?

  19. MPI: MPI publishes Half-year Report for the first half of 2017Read the original story

    Aug 31, 2017 | GlobeNewswire

    Hoersholm, Denmark, August 31, 2017 - Medical Prognosis Institute A/S announces the company's Half-year report for the period January-June 2017. The report is available as an attached document to this press release and on the company's website .

    Comment?

  20. Clinigen Receives EC Approval For Updates To Cardioxane Product InformationRead the original story

    Aug 7, 2017 | BioSpace

    Clinigen Group plc , the global pharmaceutical and services company, announces that its Commercial Medicines operation received a European Commission approval to update the current product information for Cardioxane. Cardioxane is an oncology support drug that prevents chronic cumulative cardiotoxicity caused by high dose anthracycline chemotherapy.

    Comment?